Hjem › Diffus sclerodermi › Pennsylvania › Philadelphia
Diffus sclerodermi kliniske forsøg i Philadelphia, PA
4 studier for Diffus sclerodermi søger deltagere på steder i og omkring Philadelphia (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.
Officiel studietekst (engelsk)
Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →
EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
RekruttererFase 2
- EncompaSSc site in Philadelphia, PA, Philadelphia
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
RekruttererFase 3
- GSK Investigational Site, Philadelphia
- GSK Investigational Site, Philadelphia
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
RekruttererFase 2/3
- GSK Investigational Site, Philadelphia
- GSK Investigational Site, Philadelphia
Platform Clinical Study for Conquering Scleroderma
RekruttererFase 2
- University of Pennsylvania, Philadelphia
- Thomas Jefferson University Hospital, Philadelphia
Diffus sclerodermi forsøg i andre byer
- New York City, NY8 studier
- Ann Arbor, MI7 studier
- Chicago, IL7 studier
- Durham, NC6 studier
- Los Angeles, CA6 studier
- Houston, TX5 studier
- Boston, MA5 studier
- Baltimore, MD5 studier
- New Orleans, LA4 studier
- Pittsburgh, PA4 studier
- Kansas City, KS4 studier
- Plantation, FL3 studier
Andre studier i Philadelphia
- Kræft (alle typer)59 studier
- Brystkræft56 studier
- Ikke-småcellet lungecancer51 studier
- Metastatisk cancer46 studier
- Colorektal kræft44 studier
- Ægstockræft44 studier
- Prostatakræft44 studier
- Lungecancer36 studier
- Akut myeloid leukæmi34 studier
- Hjertesvigt31 studier
- Livmoderslimhindekræft28 studier
- Depression26 studier
Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.